Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 4/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1513056 | 0.87 | ALDH1A1 (0.55) | PIM1MKNK1LRRK2IDO1MAPK14 | |
| SCHEMBL30931548 | 0.87 | ALDH1A1 (0.55) | PIM1MKNK1LRRK2IDO1MAPK14 | |
| SCHEMBL25029271 | 0.82 | ALDH1A1 (0.54) | PIM1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL27947482 | 0.82 | IDO1 (0.50) | PIM1LRRK2IDO1PIM2PIM3 | |
| SCHEMBL9877148 | 0.82 | PDPK1 (0.49) | LRRK2IDO1MAPK1KDM4EALDH1A1 | |
| SCHEMBL17922026 | 0.81 | LRRK2 (0.41) | PIM1LRRK2IDO1PIM2PIM3 | |
| SCHEMBL29989469 | 0.78 | MAPK1 (0.48) | LRRK2MAPK1 | |
| SCHEMBL2505329 | 0.78 | TBK1 (0.41) | PIM1LRRK2IDO1MAPK13MAPK12 | |
| SCHEMBL10452107 | 0.76 | LRRK2 (0.62) | LRRK2IDO1MAPK1KDM4EALDH1A1 | |
| SCHEMBL1639739 | 0.76 | LRRK2 (0.67) | PIM1LRRK2IDO1MAPK14PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611131-A1 | PYRAZOLOPYRIDINE DERIVATES | J. Uriach y Compagnia S.A. (ES) | 2006-01-04 | — | — | EP | claimed |
| WO-2004076450-A1 | PYRAZOLOPYRIDINE DERIVATES | J. Uriach Y Compañia S.A. (ES) | 2004-09-10 | — | — | WO | claimed |
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| US-20110212961-A1 | Pyrazole Derivatives as Kinase Inhibitors | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2011-09-01 | — | — | US | disclosed |
| US-7951832-B2 | Pyrazole derivatives as kinase inhibitors | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | disclosed |
| US-20090286983-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| US-20090124621-A1 | PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | disclosed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | disclosed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167040-A1 | Pyrazolopyridine derivates | MAPK1, MAP4K2, MAP4K3 | PIM1 137/4885MKNK1 114/4885LRRK2 1213/4885 |
| US-20090124621-A1 | PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | BRAF, MAP3K1, MAP3K3 | PIM1 284/4885MKNK1 48/4885LRRK2 391/4885 |
| US-20090286983-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | PIM1 196/4885MKNK1 82/4885LRRK2 845/4885 |
| US-20110212961-A1 | Pyrazole Derivatives as Kinase Inhibitors | BRAF, MAP3K1, MAP3K3 | PIM1 284/4885MKNK1 48/4885LRRK2 391/4885 |
| US-20090005377-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | PIM1 196/4885MKNK1 82/4885LRRK2 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.